Dendreon Appoints Lindsay Rocco to Lead Corporate Communications

  Dendreon Appoints Lindsay Rocco to Lead Corporate Communications

Business Wire

BRIDGEWATER, N.J. -- November 14, 2012

Dendreon Corporation (NASDAQ: DNDN) today announced the appointment of Lindsay
Rocco as executive vice president, corporate communications and member of the
executive committee, effective immediately. In this role, Ms. Rocco will be
responsible for all communications functions of the Company and will report
directly to John H. Johnson, chairman, president and chief executive officer
of Dendreon.

Ms. Rocco has extensive healthcare communications experience with large
pharmaceutical companies as well as specialized public relations agencies.
Most recently, she was senior vice president and a member of the leadership
team at Rx Mosaic Health, a specialty healthcare public relations agency
within the Omnicom Group. She helped to build and grow Rx Mosaic Health since
its establishment six years ago, and served as a senior communications
strategist for biotechnology and pharmaceutical clients within competitive and
challenging therapeutic categories, including oncology, rheumatology and
neurology.

“We are pleased to welcome Lindsay to Dendreon,” said John H. Johnson,
chairman, president and chief executive officer of Dendreon. “Lindsay is a
seasoned communicator with a deep understanding of the oncology space and a
true passion for Dendreon’s mission to help advanced prostate cancer patients
lead longer and better lives. Lindsay’s energy and expertise in healthcare
communications makes her an ideal addition to our leadership team.”

Ms. Rocco added, “I am honored to join Dendreon at such an important time for
the Company. I look forward to being a member of the executive committee and
working together with the entire organization to help transform Dendreon from
a pioneer to a leader in immunotherapy.”

Prior to joining Rx Mosaic Health, Ms. Rocco served as a director, public
affairs at Roche-Genentech. Throughout her career, Ms. Rocco has also held
senior-level positions with several healthcare public relations agencies
within global holding companies, including the Omnicom Group and Publicis, and
with MCS Healthcare Public Relations, an independent agency.

Ms. Rocco holds a Bachelor of Business Administration in Marketing from the
Joseph A. Sellinger School of Business Administration and Management at Loyola
University in Maryland. She currently serves on the Board of Governors for the
New York Chapter of the Arthritis Foundation.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target
cancer and transform lives through the discovery, development,
commercialization and manufacturing of novel therapeutics. The Company applies
its expertise in antigen identification, engineering and cell processing to
produce active cellular immunotherapy (ACI) product candidates designed to
stimulate an immune response in a variety of tumor types. Dendreon's first
product, PROVENGE^® (sipuleucel-T), was approved by the U.S. Food and Drug
Administration (FDA) in April 2010. Dendreon is exploring the application of
additional ACI product candidates and small molecules for the potential
treatment of a variety of cancers. The Company is headquartered in Seattle,
Washington and is traded on the NASDAQ Global Market under the symbol DNDN.
For more information about the Company and its programs, visit
http://www.dendreon.com/.

Contact:

Dendreon Corporation
Investor Relations
Nicole Soley, 206-455-2220
InvestorRelations@dendreon.com
or
Joele Frank, Wilkinson Brimmer Katcher
Media Relations
Andrew Brimmer, 212-355-4449
abrimmer@joelefrank.com
 
Press spacebar to pause and continue. Press esc to stop.